Form 8K Profusa Inc For: 16 September
- Investing.com
Metrics to compare | PFSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.6x | −0.4x | |
PEG Ratio | - | −0.05 | 0.00 | |
Price / Book | 0.0x | 3.1x | 2.6x | |
Price / LTM Sales | - | 1.4x | 3.1x | |
Upside (Analyst Target) | - | 81.0% | 52.9% | |
Fair Value Upside | Unlock | 19.7% | 6.4% | Unlock |
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.